On the public citation graph

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis

0 signed · 95 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s10637-015-0284-9openalex-snapshot
Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement–positive non–small cell lung cancer treated with alectinib
inferredcites →https://doi.org/10.1007/s10654-010-9491-zopenalex-snapshot
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
inferredcites →https://doi.org/10.1016/j.cell.2007.11.025openalex-snapshot
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
inferredcites →https://doi.org/10.1016/j.cllc.2017.10.008openalex-snapshot
Lung Toxicity in Non–Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature
inferredcites →https://doi.org/10.1016/s0140-6736(17)30123-xopenalex-snapshot
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
inferredcites →https://doi.org/10.1016/s1470-2045openalex-snapshot
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.
inferredcites →https://doi.org/10.1016/s1470-2045(13)70142-6openalex-snapshot
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
inferredcites →https://doi.org/10.1016/s1470-2045(13)70510-2openalex-snapshot
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(14)70362-6openalex-snapshot
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
inferredcites →https://doi.org/10.1016/s1470-2045(15)00488-xopenalex-snapshot
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(15)00614-2openalex-snapshot
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30392-8openalex-snapshot
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30072-4openalex-snapshot
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30339-xopenalex-snapshot
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
inferredcites →https://doi.org/10.1038/nature05945openalex-snapshot
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
inferredcites →https://doi.org/10.1038/nature05984openalex-snapshot
Positive darwinian selection at the imprinted MEDEA locus in plants
inferredcites →https://doi.org/10.1056/nejmoa1006448openalex-snapshot
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1011205openalex-snapshot
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
inferredcites →https://doi.org/10.1056/nejmoa1214886openalex-snapshot
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1408440openalex-snapshot
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1410490openalex-snapshot
Surgical Treatment of Moderate Ischemic Mitral Regurgitation
inferredcites →https://doi.org/10.1056/nejmoa1704795openalex-snapshot
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1093/jjco/hyu183openalex-snapshot
Interstitial lung disease induced by alectinib (CH5424802/RO5424802)
inferredcites →https://doi.org/10.1097/jto.0000000000000566openalex-snapshot
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
inferredcites →https://doi.org/10.1136/bmj.d5928openalex-snapshot
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
inferredcites →https://doi.org/10.1136/esmoopen-2017-000219openalex-snapshot
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
inferredcites →https://doi.org/10.1159/000454668openalex-snapshot
The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants
inferredcites →https://doi.org/10.1186/1471-2407-13-262openalex-snapshot
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
inferredcites →https://doi.org/10.1200/jco.2015.63.9443openalex-snapshot
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
inferredcites →https://doi.org/10.1200/jco.2015.65.5936openalex-snapshot
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK -Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
inferredcites →https://doi.org/10.1200/jco.2016.34.15_suppl.9058openalex-snapshot
Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).
inferredcites →https://doi.org/10.1200/jco.2017.77.5841openalex-snapshot
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
inferredcites →https://doi.org/10.1634/theoncologist.2017-0629openalex-snapshot
Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile
inferredcites →https://doi.org/10.18632/oncotarget.18536openalex-snapshot
Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
inferredcites →https://doi.org/10.18632/oncotarget.25154openalex-snapshot
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
inferredcites →https://doi.org/10.2188/jea.15.235openalex-snapshot
Systematic Evaluation and Comparison of Statistical Tests for Publication Bias

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4856228openalex-extracted
Drug-Induced Liver Injury Associated with Alk Inhibitors: A Pharmacovigilance Analysis of the Fda Adverse Event Reporting System (Faers)
inferred← citeshttps://doi.org/10.1002/cam4.6241openalex-snapshot
A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK ‐positive non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1002/ccr3.4278openalex-snapshot
Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK ‐positive non‐small‐cell lung cancer: Case report and review of the literature
inferred← citeshttps://doi.org/10.1002/pbc.30516openalex-snapshot
EML4::ALK fusions in complex lymphatic malformations
inferred← citeshttps://doi.org/10.1007/s13402-021-00616-xopenalex-snapshot
Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis
inferred← citeshttps://doi.org/10.1016/j.bulcan.2022.04.014openalex-snapshot
When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study
inferred← citeshttps://doi.org/10.1016/j.canrad.2023.06.002openalex-snapshot
Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review
inferred← citeshttps://doi.org/10.1016/j.ejca.2026.116221openalex-snapshot
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.esmoop.2021.100315openalex-snapshot
Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
inferred← citeshttps://doi.org/10.1016/j.jddst.2020.102204openalex-snapshot
Formulation and evaluation of self-nanoemulsifying drug delivery system of brigatinib: Improvement of solubility, in vitro release, ex-vivo permeation and anticancer activity
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2021.100157openalex-snapshot
Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.1016/j.lungcan.2025.108717openalex-snapshot
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC
inferred← citeshttps://doi.org/10.1016/j.medcle.2020.04.060openalex-snapshot
Cryptogenic organizing pneumonia by alectinib
inferred← citeshttps://doi.org/10.1016/j.medcli.2020.04.058openalex-snapshot
Neumonía organizada criptogenética por alectinib
inferred← citeshttps://doi.org/10.1016/s1155-195x(21)42935-xopenalex-snapshot
10.1016/s1155-195x(21)42935-x
inferred← citeshttps://doi.org/10.1080/14737140.2026.2665836openalex-snapshot
Complications following small-molecule inhibitors for non-small cell lung cancer
inferred← citeshttps://doi.org/10.1080/14740338.2023.2234279openalex-snapshot
Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
inferred← citeshttps://doi.org/10.1080/14740338.2025.2467830openalex-snapshot
Hepatic adverse events associated with anaplastic lymphoma kinase tyrosine kinase inhibitors: a disproportionality analysis based on FAERS database and analysis of drug-gene interaction network
inferred← citeshttps://doi.org/10.1080/14756366.2025.2518491openalex-snapshot
Synergistic optimizations of efficacy and membrane permeability of IRAK4 inhibitors: identifying new lead compounds for anti-inflammatory therapeutics
inferred← citeshttps://doi.org/10.1111/1759-7714.13817openalex-snapshot
ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1111/1759-7714.14824openalex-snapshot
Efficacy and safety of anaplastic lymphoma kinase inhibitors for non–small cell lung cancer: A systematic review and network meta‐analysis
inferred← citeshttps://doi.org/10.1136/bmjopen-2023-078173openalex-snapshot
Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1139/cjpp-2025-0065openalex-snapshot
Disproportionality analysis of ALK inhibitor-induced hemolytic adverse events: a pharmacovigilance study using the FDA Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.1183/2312508x.10028019openalex-snapshot
Cardiovascular effects of innovative therapies in lung cancer
inferred← citeshttps://doi.org/10.1186/s10020-020-00193-zopenalex-snapshot
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
inferred← citeshttps://doi.org/10.1186/s10020-021-00400-5openalex-snapshot
ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1186/s12885-020-07412-0openalex-snapshot
The role of CD28 in the prognosis of young lung adenocarcinoma patients
inferred← citeshttps://doi.org/10.1186/s12885-021-08977-0openalex-snapshot
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
inferred← citeshttps://doi.org/10.1186/s12964-022-00958-5openalex-snapshot
ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production
inferred← citeshttps://doi.org/10.1186/s12964-023-01065-9openalex-snapshot
Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
inferred← citeshttps://doi.org/10.1186/s12967-023-04212-5openalex-snapshot
Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy
inferred← citeshttps://doi.org/10.1212/nxi.0000000000000735openalex-snapshot
Anaplastic lymphoma kinase inhibitor-associated myositis
inferred← citeshttps://doi.org/10.1530/erc-20-0436openalex-snapshot
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
inferred← citeshttps://doi.org/10.21037/tlcr-20-1109openalex-snapshot
How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
inferred← citeshttps://doi.org/10.21037/tlcr-22-638openalex-snapshot
Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease
inferred← citeshttps://doi.org/10.2147/ott.s340984openalex-snapshot
Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report
inferred← citeshttps://doi.org/10.2174/0113816128342778250218105338openalex-snapshot
Targeting Anaplastic Lymphoma Kinase in Oncology: Identification and Computational Validation of Novel Inhibitors for Anaplastic Large Cell Lymphoma, Non-small Cell Lung Cancer, and Neuroblastoma
inferred← citeshttps://doi.org/10.3174/ajnr.a6477openalex-snapshot
Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1369118openalex-snapshot
Nephrotoxicity of targeted therapy used to treat lung cancer
inferred← citeshttps://doi.org/10.3389/fonc.2025.1572425openalex-snapshot
Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4–ALK+ metastatic non-small cell lung adenocarcinoma
inferred← citeshttps://doi.org/10.3389/fphar.2022.858279openalex-snapshot
Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
inferred← citeshttps://doi.org/10.3389/fphar.2023.1016976openalex-snapshot
Lung cancer, comorbidities, and medication: the infernal trio
inferred← citeshttps://doi.org/10.3389/fphar.2024.1361443openalex-snapshot
Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis
inferred← citeshttps://doi.org/10.3389/pore.2022.1610694openalex-snapshot
On-Target Side Effects of Targeted Therapeutics of Cancer
inferred← citeshttps://doi.org/10.3390/cancers13081966openalex-snapshot
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer
inferred← citeshttps://doi.org/10.3390/ijms222212244openalex-snapshot
Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
inferred← citeshttps://doi.org/10.3390/jpm14070670openalex-snapshot
Clinical and Molecular Traits of a Novel SPECC1L-ALK Fusion in a Patient with Advanced Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3390/pediatric15020029openalex-snapshot
Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?
inferred← citeshttps://doi.org/10.3390/ph13110374openalex-snapshot
Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3892/or.2020.7911openalex-snapshot
Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review)
inferred← citeshttps://doi.org/10.5603/ocp.2020.0019openalex-snapshot
The role of diagnostics and treatment — lung cancer with ALK rearrangement
inferred← citeshttps://doi.org/10.6004/jnccn.2021.7056openalex-snapshot
Targeted Therapy in a Young Adult With a Novel Epithelioid Tumor Driven by a PRRC2B-ALK Fusion.
inferred← citeshttps://doi.org/10.6084/m9.figshare.12599313openalex-snapshot
Additional file 1 of Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
inferred← citeshttps://doi.org/10.6084/m9.figshare.12599316openalex-snapshot
Additional file 2 of Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
inferred← citeshttps://doi.org/10.6084/m9.figshare.12997261openalex-snapshot
Additional file 1 of The role of CD28 in the prognosis of young lung adenocarcinoma patients
inferred← citeshttps://doi.org/10.6084/m9.figshare.21332692openalex-snapshot
Additional file 2 of ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production
inferred← citeshttps://doi.org/10.6084/m9.figshare.21332698openalex-snapshot
Additional file 4 of ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production
inferred← citeshttps://doi.org/10.6084/m9.figshare.22625759openalex-snapshot
Additional file 4 of Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
inferred← citeshttps://doi.org/10.6084/m9.figshare.22625762openalex-snapshot
Additional file 5 of Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.